Key clinical point: Denosumab every 3 months could help reduce bone turnover markers and bone pain in patients with fibrous dysplasia/McCune-Albright syndrome (FD/MAS) that is refractory to bisphosphonate therapy.
Major finding: After treatment with denosumab, serum alkaline phosphatase activity and propeptide of type 1 procollagen levels were respectively reduced from 212 IU/L to 79 IU/L (P = .004) and from 346.2 ng/mL to 55.7 ng/mL (P = .023) and normalized in 70% and 75% of patients, respectively.
Study details: Case series of 12 with polyostotic FD/MAS, treated with long-term bisphosphonates and reporting bone pain and an increase in markers for bone turnover, who then received denosumab 60 mg.
Disclosures: Two authors received funding from the Bontius Foundation, a nonprofit institution supporting research within the Leiden University Medical Center. The authors reported no conflicts of interest.
Bas CJ et al. J Clin Endocrinol Metab. 2019;104(12):6069-78.